dc.contributor.author | Žilionytė, Karolina | |
dc.contributor.author | Bagdzevičiūtė, Ugnė | |
dc.contributor.author | Mlynska, Agata | |
dc.contributor.author | Urbštaitė, Elena | |
dc.contributor.author | Paberalė, Emilija | |
dc.contributor.author | Darulytė, Neringa | |
dc.contributor.author | Krasko, Jan Aleksander | |
dc.contributor.author | Pašukonienė, Vita | |
dc.date.accessioned | 2023-09-18T16:16:39Z | |
dc.date.available | 2023-09-18T16:16:39Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0340-7004 | |
dc.identifier.other | (PMID)35364740 | |
dc.identifier.uri | https://etalpykla.vilniustech.lt/handle/123456789/112536 | |
dc.description.abstract | Low efficacy of cancer immunotherapy encourages the search for possible resistance mechanisms and biomarkers that would predict the outcome of immunotherapy in oncology patients. Most cancer immunotherapies act on T lymphocytes, which can specifically recognize and kill tumor cells. However, for immunotherapy-activated T lymphocytes to be able to perform these functions, proper tumor Ag processing and surface presentation by MHC-I molecule is important. Knowing the significance of Ag processing and presentation mechanism (APM) in anti-tumor immune response, we sought to evaluate how the functionality of APM affects tumor immune microenvironment and response to dendritic cell vaccines (DCV) and anti-PD-1. By comparing murine Lewis lung carcinoma LLC1 and glioma GL261 models a decreased expression of APM-related genes, such as Psmb8, Psmb9, Psmb10, Tap1, Tap2, Erap1, B2m, and low expression of surface MHC-I molecule were found in LLC1 cells. Changes in APM-related gene expression affected the ability of T lymphocytes to recognize and kill LLC1 cells, resulting in the absence of cytotoxic immune response and resistance to DCV and anti-PD-1. An emerging cytotoxic immune reaction and sensitivity to DCV and anti-PD-1 were observed in GL261 tumors where APM remained functional. This study demonstrates that one of the possible mechanisms of tumor resistance to immunotherapy is a dysfunctional APM and reveals a predictive potential of APM-related gene set expression for the personalization of dendritic cell vaccine and anti-PD-1 therapies in murine pre-treated tumors. | eng |
dc.format | PDF | |
dc.format.extent | p. 2691-2700 | |
dc.format.medium | tekstas / txt | |
dc.language.iso | eng | |
dc.relation.isreferencedby | MEDLINE | |
dc.relation.isreferencedby | Science Citation Index Expanded (Web of Science) | |
dc.relation.isreferencedby | Scopus | |
dc.source.uri | https://link.springer.com/article/10.1007/s00262-022-03190-9 | |
dc.title | Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models | |
dc.type | Straipsnis Web of Science DB / Article in Web of Science DB | |
dcterms.references | 31 | |
dc.type.pubtype | S1 - Straipsnis Web of Science DB / Web of Science DB article | |
dc.contributor.institution | Nacionalinis vėžio institutas Vilniaus universitetas | |
dc.contributor.institution | Nacionalinis vėžio institutas Vilniaus Gedimino technikos universitetas | |
dc.contributor.institution | Vilniaus universitetas | |
dc.contributor.institution | Nacionalinis vėžio institutas | |
dc.contributor.faculty | Fundamentinių mokslų fakultetas / Faculty of Fundamental Sciences | |
dc.subject.researchfield | N 010 - Biologija / Biology | |
dc.subject.researchfield | N 003 - Chemija / Chemistry | |
dc.subject.vgtuprioritizedfields | FM0202 - Ląstelių ir jų biologiškai aktyvių komponentų tyrimai / Investigations on cells and their biologically active components | |
dc.subject.ltspecializations | L105 - Sveikatos technologijos ir biotechnologijos / Health technologies and biotechnologies | |
dc.subject.en | Ag processing and presentation mechanism | |
dc.subject.en | Anti-PD-1 | |
dc.subject.en | Dendritic cell vaccine | |
dc.subject.en | Experimental tumor models | |
dc.subject.en | Immunogenicity | |
dc.subject.en | Predictive biomarkers | |
dcterms.sourcetitle | Cancer immunology, immunotherapy | |
dc.description.issue | 11 | |
dc.description.volume | 71 | |
dc.publisher.name | Springer | |
dc.identifier.doi | 35364740 | |
dc.identifier.doi | 000777287500001 | |
dc.identifier.doi | 10.1007/s00262-022-03190-9 | |
dc.identifier.elaba | 125651385 | |